Loading...
 
Mediterr J Rheumatol 2020;31(4):400-5
The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review
Authors Information

1. Division of Rheumatology, Department of Internal Medicine, 2. Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Medical Center, Beirut, Lebanon

References
  1. Kornbluth A. Infliximab Approved for Use in Crohn’s Disease: A Report on the FDA GI Advisory Committee Conference. Inflamm Bowel Dis 1998;4:328-9.
  2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet Lond Engl 1999;354:1932-9.
  3. Uthman I, Mroueh K, Arayssi T, Nasr F, Masri AF. The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon. Semin Arthritis Rheum 2004;33:422-3.
  4. Musallam KM, Arayssi T, Taher AT, Kanj N, Uthman I. The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon. Rheumatol Int 2008;29:1255.
  5. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2008;6:1212-7; quiz 1176.
  6. Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects of infliximab therapy in Crohn’s disease. Expert Opin Drug Saf 2016;15:769-75.
  7. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy. Emerg Infect Dis 2009;15:1556-61.
  8. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther 2015 Nov 11;17:319.
  9. Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev 2017;16:1185-95.
  10. Buch MH, Rubbert-Roth A, Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012;11:558-62.
  11. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
  12. Wakabayashi H, Hasegawa M, Nishioka Y, Minami Y, Nishioka K, Sudo A. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Clin Rheumatol 2013;32:253-9.
  13. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2015;74:979-84.
  14. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601-8.
  15. Costa Jde O, Lemos LL, Machado MA, Almeida AM, Kakehasi AM, Araújo Vde E, et al. Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Rev Bras Reumatol 2015;55:146-58.
  16. Bae S-C, Lee YH. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J Rheum Dis 2018;21:922-9.
  17. Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Int J Rheum Dis 2012;15:330-5.
  18. Lutf A, Poil AR, Hammoudeh M. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study. Int J Rheum Dis 2014;17:63-5.
  19. Mansouri LE, Bahiri R, Abourazzak FE, Abouqal R, Hajjaj-Hassouni N. Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int 2009;29:1423.
  20. Dargham SR, Zahirovic S, Hammoudeh M, Al Emadi S, Masri BK, Halabi H, et al. Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PloS One 2017;13:e0208240.
  21. Araj G, Saade A, Itani L. Tuberculosis Burden in Lebanon: Evolution and Current Status. Leban Med J 2006;64:1-7.